The feasibility of utilizing adenovirus-mediated human oligopeptide transporter (hPEPT1) gene transfer to achieve peptide drug delivery to the brain across the blood-brain barrier (BBB) was tested by examining the accumulation of model peptides in a rat brain endothelial cell line (RBEC1) and rat brain after transduction with a recombinant adenovirus encoding hPEPT1-enhanced yellow fluorescent protein fusion gene (AdhPEPT1-EYFP). In vitro uptake of [ 3 H]GlySar was determined in RBEC1
. Possible roles of peptides in the CNS include; 1) involvement in neurotransmission and neuromodulation; 2) regulation of the neuroendocrine axis; 3) regulation of cerebral blood flow; 4) regulation of CSF secretion; 5) mediation of the integrity of the BBB; 6) modulation of the BBB permeability to nutrients; 7) regulation of water and electrolyte contents of the brain; 8) regulation of the expression of specific proteins at the BBB. There are several disorders of the brain in which peptides are known to be implicated in the pathogenesis, such as Alzheimer's disease (AD), depression, stroke, and so on. Thus, peptide drugs may be useful to treat or to diagnose brain disease. However, delivery of peptide drugs to the brain is an essential prerequisite for therapeutic effectiveness, since distribution of peptides and proteins to the brain is generally very low because of the blood-brain barrier (BBB) that prevents many molecules from crossing into the brain. The anatomical basis of the BBB arises from special cellular features of brain capillary endothelial cells, which include tight junctions, and minimal pinocytosis and fenestration (Pardridge, 2002) . The BBB is well known to have several transport systems that regulate the concentration and entry of solutes into the central nervous system (CNS) (Tsuji and Tamai, 1999) . They include 1) carrier-mediated transport (CMT), 2) receptor-mediated transcytosis (RMT), and 3) adsorptive-mediated transcytosis (AMT). Thus, various transporters and receptors are expressed at the BBB.
However, it is difficult for peptides to penetrate the BBB, as they are hydrophilic, biologically unstable, and usually large in size (Banks and Kastin, 1994) .
The oligopeptide transporter PEPT1 accepts not only dipeptides and tripeptides as substrates, but also peptide-mimetic drugs such as beta-lactam antibiotics (Fei et al., 1994; Liang et al., 1995; Miyamoto et al., 1996; Sai et al., 1996; or Tamai et al., 1997) , This (Hu and Amidon, 1988) , the anti-viral drug valacyclovir (Balimane et al., 1998) and the anti-cancer drug bestatin (Saito and Inui, 1993) . The physiological role of oligopeptide transporters lies in the (re)absorption of peptides from the intestinal and renal tubular lumen. However, no transporter or transport activity for di-or tripeptides has been found at the BBB.
There have been several experimental trials aimed at utilizing endogenously expressed oligopeptide transport activity for improving oral bioavailability , or for tumor targeting, using cultured cells such as human fibrosarcoma cell line HT-1080 (Nakanishi et al., 1997) , and human pancreatic cell lines AsPc-1 and Capan-2 (Gonzalez et al., 1998) that express oligopeptide transport activity. We previously examined the feasibility of tumor-selective delivery of dipeptides or peptide-mimetic drugs by utilizing the oligopeptide transport activity (Nakanishi et al., 2000) . However, to our knowledge, there has been no experimental trial on drug delivery to the brain by utilizing the activity of oligopeptide transporter in the BBB, since it is not expressed at the BBB.
It was, therefore, the purpose of the present study to examine the feasibility of delivering peptide drugs to the brain by heterologous expression of human oligopeptide transporter at the brain capillary endothelial cells, which make up the BBB. In our previous study, we constructed a recombinant adenovirus containing human PEPT1 and enhanced yellow fluorescent protein (AdhPEPT1-EYFP) fusion gene (Toyobuku et al., 2002) . In that study, heterologous expression of hPEPT1-EYFP in mouse liver greatly enhanced delivery of peptide-mimetics to the liver. In the present study, oligopeptide transport activity was assessed in a brain endothelial cell line, RBEC1 transduced with or without AdhPEPT1-EYFP in vitro. In addition, AdhPEPT1-EYFP was transduced into the brain of rats, and the distribution of cefadroxil, a substrate of the oligopeptide transporter hPEPT1, into the brain was evaluated in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. 
Construction of recombinant adenovirus encoding hPEPT1-EYFP fusion gene
The hPEPT1-EYFP fusion gene was constructed to express of hPEPT1 in in vitro-cultured cells or in vivo as described previously (Toyobuku et al., 2002) . The constructs were restriction enzyme-mapped and sequenced to determine insert orientation. The vector containing the hPEPT1-EYFP fusion gene was used to generate the replication deficient recombinant adenovirus serotype 5 encoding AdhPEPT1-EYFP driven by a cytomegalovirus (CMV) promoter (Fig. 1) . To generate pAdhPEPT1-EYFP, the 2.2-kilobase hPEPT1-EYFP insert digested with KpnI/NotI was ligated into the multiple cloning site of pShuttle-CMV vector (kindly provided by T.-C. He, Howard
Hughes Medical Institute, MD) (He et al., 1998 into primary cultured rat BCECs as described previously (Kido et al., 2000) . RBEC1
(1.0 x 10 5 cells/cm 2 ) were grown routinely in collagen type I-coated tissue flasks (Greiner Bio-one, Austria) at 37°C under a 5% CO 2 , 95% air atmosphere. The culture medium consisted of DMEM supplemented with 2 mM L-glutamine, 20 mM NaHCO 3 , 150 µg/mL endothelial cell growth supplement, 5% FBS and 5% donor horse serum.
The cells were seeded into 4-well plates (1.0 x 10 5 cells/well) 3 days before adenovirus transduction and incubated at 37°C and 5% CO 2 .
In vitro gene transfer
RBEC1 were plated onto rat tail collagen type I-coated 4-well plates (NALGE Nunc International, USA) for 3 days before transduction. Transduction of adenovirus was performed after the cells had reached 80-90% confluence, with AdhPEPT1-EYFP at the multiplicity of infection (MOI) of 100 in the presence of different ratios of poly-L-lysine. The uptake experiment was performed 1 day or 3 days after transduction.
Phase contrast and fluorescence images of the cells were obtained using a Zeiss
Axiovert À S100 microscope (Carl Zeiss Inc., Thornwood, NY) equipped with an appropriate filter.
Uptake experiment
This article has not been copyedited and formatted. The final version may differ from this version. N NaOH (0.25 mL), followed by shaking for 2 h. The resultant lysates were neutralized with 5 N HCl and mixed with 4 mL of liquid scintillation cocktail, Cleasol-I (Nacalai Tesque, Kyoto, Japan). Radioactivity was determined using a liquid scintillation counter (LSC-1000, Aloka Co. Ltd., Tokyo, Japan). Cellular protein content was measured by the method reported previously (Bradford et al., 1976 ) using BSA as a standard. Net uptake was expressed as the cell-to-medium ratio (µL/mg protein) obtained by dividing the uptake amount by the concentration of substrate in the incubation medium.
In vivo gene transfer to anesthetized rat
All the animal experiments were performed according to the Guidelines for the Care and Use of Laboratory Animals in Takara-machi Campus of Kanazawa University.
Male Wistar rats (6-8 weeks old, Japan SLC, Japan) used in this study had free access to food and water prior to sacrifice. Rats were anesthetized with an intramuscular administration of ketamine/xylazine (235/2.3 mg/kg). In vivo gene transfer to rat brain was carried out by the in situ brain perfusion technique using methods reported previously to increase the exposure of the BBB to adenovirus (Takasato et al., 1984) .
After exposure of the right carotid artery, the occipital and superior thyroid arteries 
Tissue preparation for analysis of hPEPT1-EYFP transgene expression
After sacrifice of adenovirus-transduced rats by decapitation, the cerebral hemispheres were immediately dissected and washed with saline. Then, they were quickly frozen in liquid nitrogen and stored at -80°C. For fluorescence analysis of hPEPT1-EYFP expression, resected tissues were embedded in optimal cutting temperature compound (OCT, Sakura Finetechnical Co., Ltd., Tokyo, Japan). Serial 10 µm tissue sections were prepared with a Cryostat HM505E (Carl Zeiss Inc.) at -20°C. Fluorescence images of sections were obtained using a Zeiss Axiovert S100 microscope (Carl Zeiss Inc.).
Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from AdhPEPT1-EYFP-transduced cells and frozen tissues using an RNeasy Mini Kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. Total RNA was reverse-transcribed and amplified by polymerase chain anti-mdr1 antibody-treated sample. Secondary antibody Alexa Fluor 594 goat anti-rabbit IgG (Molecular Probes, Europe BV, Netherlands, AA Leiden) diluted with 3% blocking agent in PBS at 1:100 was added to the primary anti-EGFP antibody-treated sample. Then incubation was continued for 30 min. The slide glasses were washed as described above. They were mounted in VECTASHIELD (Vector Laboratories, Inc., Burlingame, CA) and observed under a fluorescence microscope.
Cefadroxil disposition to the brain in anesthetized rats transduced with adenovirus
RESULTS

Uptake of [ 3 H]GlySar by RBEC1 transduced with AdhPEPT1-EYFP
To examine whether dipeptide transport activity is induced in the blood-brain barrier by AdhPEPT1-EYFP transduction, we evaluated [ 3 H]GlySar uptake in transduced RBEC1 at pH 6.0. As can be seen in Fig. 2A , the uptake of dipeptides increased time-dependently in AdhPEPT1-EYFP-transduced RBEC1, while that of non-transduced RBEC1 did not. RBEC1 transduced with AdhPEPT1-EYFP showed a 10 times higher uptake than that of non-transduced control cells at 5 min. On the other hand, when AdGFP was transduced into RBEC1 as a control vector at MOI 300, the uptake of [ 3 H]GlySar was similar to that of non-transduced cells (Fig. 2B ).
Unlabeled oligopeptide was included in the uptake buffer to test whether [ 3 H]GlySar uptake was inhibitable or not (Fig. 2B ). In the presence of unlabeled GlySar (10 mM) at a concentration above the apparent Km (2.8 mM) of GlySar for PEPT1, uptake of (Fei et al., 1994; Liang et al., 1995) .
Expression of hPEPT1-EYFP in RBEC1 after AdhPEPT1-EYFP transduction
This article has not been copyedited and formatted. The final version may differ from this version. To investigate whether hPEPT1-EYFP transcript was expressed in RBEC1 after AdhPEPT1-EYFP transduction, RT-PCR was conducted using specific primers based on the nucleotide sequence of hPEPT1-EYFP (Fig. 3A) . The PCR product corresponding to hPEPT1-EYFP was detected in AdhPEPT1-EYFP-transduced RBEC1.
The expression of hPEPT1-EYFP fusion protein was examined by fluorescence microscopy in RBEC1. Those cells were transduced with AdhPEPT1-EYFP at an MOI of 300. As shown in Fig. 3B , there was no detectable expression of hPEPT1-EYFP and fluorescence of hPEPT1-EYFP was below the detection level, which corresponds to the background level, despite the presence of mRNA signals.
Effect of various transduction aids on the expression of hPEPT1-EYFP in RBEC1
To improve the expression level of hPEPT1-EYFP fusion protein in RBEC1, we examined the effect of cationic transduction aids, cyclodextrin molecules and polymer, on the expression of hPEPT1-EYFP protein 24 hours after adenovirus transduction by fluorescence microscopy (Fig. 4) . Expression of hPEPT1-EYFP protein was detected at a higher level after AdhPEPT1-EYFP transduction in the presence of poly-L-lysine ( AdhPEPT1-EYFP alone (Fig. 4A ). Beta-cyclodextrin most significantly enhanced adenoviral-mediated gene transfer to RBEC1 among the cyclodextrins (Fig. 4D) .
However, cyclodextrin mildly disrupted the cell membrane and altered the shape of RBEC1 observed in the phase-contrast image (data not shown). On the other hand, addition of poly-L-lysine caused no apparent change of cell shape. The use of poloxamer 407, a viscous biocompatible polyol, as a transduction aid, did not affect the expression of hPEPT1-EYFP compared to adenovirus alone (Fig. 4H) . So, poly-L-lysine was suggested to improve the efficiency of transduction.
Effect of addition ratio of poly-L-lysine during transduction on the expression of hPEPT1-EYFP in RBEC1
To find the optimal conditions as regards poly-L-lysine, we prepared mixtures of adenovirus with poly-L-lysine to investigate whether hPEPT1-EYFP transgene expression in RBEC1 was dependent on the ratio of poly-L-lysine to adenovirus during transduction (Fig. 5) . The expression level of hPEPT1-EYFP increased with increasing ratio of poly-L-lysine up to 1,000 molecules per adenovirus particle (Figs. 5A , B and C).
When RBEC1 was transduced with AdhPEPT1-EYFP and 3,000 molecules of poly-L-lysine per particle, transgene expression appeared to be similar to that in the case of 1,000 molecules of poly-L-lysine (Fig. 5D ).
Expression of hPEPT1-EYFP in rat brain after AdhPEPT1-EYFP transduction
To investigate whether hPEPT1-EYFP transcript was expressed in vivo after administration of AdhPEPT1-EYFP to rat, RT-PCR analysis of hPEPT1-EYFP was conducted. After transduction at the virus dose of 3.2 x 10 9 PFU per rat, mRNA of hPEPT1-EYFP was detected in the rat brain (Fig. 6A ). In addition, in order to evaluate whether hPEPT1-EYFP protein was induced in vivo after AdhPEPT1-EYFP transduction, expression in brain was examined by fluorescence microscopy of brain slices (Fig. 6B ). At the virus dose of 3.2 x 10 9 PFU per rat, hPEPT1-EYFP fluorescence was observed (Fig. 6B (b) ), while no fluorescence signal was observed in the case of transduction without AdhPEPT1-EYFP ( Fig. 6B (a) ).
The intracellular localization of hPEPT1-EYFP was examined by immunofluorescence studies of rat brain cryosections (Fig. 6B (c) and (d) ). The apical membrane marker P-glycoprotein was immunostained with monoclonal antibody C219 as the primary antibody. hPEPT1-EYFP fusion protein was detected with anti-EGFP antibody ( (d)). Morphologically, the distribution of hPEPT1-EYFP fluorescence appeared to be at least partly co-localized with that of P-glycoprotein.
Drug disposition to the brain of AdhPEPT1-EYFP-transduced rat
To evaluate whether the disposition of dipeptides was improved after AdhPEPT1-EYFP transduction of rats, the distribution of cefadroxil to the brain was measured at 30 min after administration, and Kp values, which were obtained by dividing the total concentration of cefadroxil in the brain by that in plasma, were evaluated. [ 14 C]Inulin was employed to estimate the distribution in the extracellular fluid space, because it hardly enters the cell (Tsuji et al., 1983) . As shown in Fig. 7 , in the brain of rats transduced with AdhPEPT1-EYFP at the dose of 3.2 x 10 9 PFU per rat, the Kp value of cefadroxil was increased about 2 times compared with that in non-transduced rats, though this was not statistically significant. 
Discussion
The entry of most polar molecules and proteins into the brain from circulating blood is restricted by the endothelial wall, that is, the BBB. Peptides do not readily penetrate the BBB, because they are hydrophilic, biologically unstable, large molecules. Even small di-or tri-peptides, such as beta-lactam antibiotics, that are used for the treatment of central nervous system infections, seem to cross the blood-brain barrier in only negligible amounts, which do not differ from those of extracellular markers (Torok et al., 1998) . PEPT1 or PEPT2 expressed in intestinal and renal epithelial cells transport small peptides such as di-and tripeptides. However, it has not been clarified whether peptide transporters exist at the BBB. Therefore, in the current study, we attempted to induce expression of the oligopeptide transporter hPEPT1 in rat endothelial wall, by utilizing a recombinant adenovirus, in order to examine the feasibility of this approach for drug delivery to the brain.
Craniotomy-based drug delivery, including either intraventricular drug infusion or local intracerebral implants, can be used to deliver a very small volume <1 mm 3 , from a local depot site (Pardridge, 2002) . However, it is desirable to develop a system to transport target molecules across the BBB and supply them widely throughout the brain after intravenous administration. Therefore, we have attempted to express human oligopeptide transporter at the BBB in order to utilize its transport activity for the delivery of drugs to the brain. For delivery of drugs from the systemic circulation to the brain across the BBB under physiological conditions, we must take into consideration that the pH of the systemic circulation is 7.4. In our study, significant uptake of was also observed at pH 7.5 (Covitz et al., 1996) . Gonzalez et al. reported transport activity of [ 3 H]GlySar in AsPc-1 and Capan-2 cells at pH 7.4 (Gonzalez et al., 1998) , in accordance with the present findings. In our previous report, uptake of the dipeptide carnosine was observed at pH 7.4 in AdhPEPT1-EYFP transduced WIFB9 cells used as a model of polarized liver cells (Toyobuku et al., 2002) . Furthermore, Guo et al. reported that the optimum pH for valacyclovir uptake was pH 7.5 (Guo et al., 1999) . On the other hand, it has been reported that Na + /H + antiporter (NHE1) is present at the endothelial cell membrane (Kalaria et al., 1998) . Thus, the environment might be made more acidic in the close vicinity of the endothelial cells by the action of NHE1. In any event, hPEPT1-EYFP fusion protein was functional in medium of neutral pH in BBB model cells transduced with AdhPEPT1-EYFP.
It is generally difficult to transfer a foreign gene to the blood vessels from the systemic circulation in vivo. In our present study, the expression level of hPEPT1-EYFP fusion protein in RBEC1 was very low, although mRNA of hPEPT1-EYFP was observed and was functional in vitro (Fig. 3 ). However, the expression level of hPEPT1-EYFP in RBEC1 was improved when a cationic polymer, such as poly-L-lysine, was included during the transduction process (Fig. 4 (B) ). Toyoda et al. reported a similar result in vascular cells (Toyoda et al., 1998) . We also demonstrated that the expression level of hPEPT1-EYFP in rat brain in vivo was improved by the presence of poly-L-lysine during transfection (Fig. 6 ). This may be due to enhancement of the electrostatic interaction of adenovirus with the cell surface, favoring subsequent virus-mediated steps.
Croyle et al. reported that the expression level of GFP in rat small intestine was improved when beta cyclodextrin was used during the transduction (Croyle et al., 1998) .
However, cyclodextrins significantly reduced transepithelial electrical resistance. We found that the morphology of RBEC1 observed under a phase-contrast microscope The localization of hPEPT1-EYFP is critical, if the transporter is to deliver peptide drugs from the systemic circulation into the brain. Membrane transporters such as GLUT1 or choline transporter at the BBB take up drugs or endogenous compounds from the circulation in the brain. Our results showed that hPEPT1-EYFP was expressed in RBEC1 after adenovirus transduction (Fig. 4 (B) ). However, the localization of hPEPT1-EYFP was not clear in this study. Sun et al. detected hPEPT1-GFP at the apical and basolateral membranes of Caco-2 cells (Sun et al., 2001) . It was reported that hPEPT1 was present in the plasma membrane and intracellular vesicular structures of AsPC-1 and Capan-2 cells (Gonzalez et al., 1998) . hPEPT1 is localized in nuclei of vascular smooth muscle cells and lysosomes of the exocrine pancreas (Bockman et al., 1997) . Thus, the distribution of hPEPT1 in various cells is diverse. In our present study, the Kp value of cefadroxil in AdhPEPT1-EYFP-transduced rat brain was increased after intravenous injections. Therefore, the hPEPT1-EYFP fusion protein is considered to be functional at least in the luminal membrane of the rat BBB. This is desirable for delivery of peptide drugs from the systemic circulation into the brain. However, significant cytoplasmic staining was also observed in RBEC1, probably due to the overexpression of the transporter. Further investigation on co-localization of hPEPT1-EYFP with various subcellular markers is needed.
Recently, Berger and Hediger reported that PEPT2 mRNA is expressed in brain, especially in astrocytes, subependymal cells, ependymal cells and epithelial cells of the choroid plexus (Berger and Hediger, 1999) . Furthermore, the peptide transporter PEPT2
was recently shown to be functional in rat choroid plexus, suggesting that it may play a This article has not been copyedited and formatted. The final version may differ from this version. Another oligopeptide transporter, PHT1, responsible for transport of histidine oligopeptides and histidine itself, has been cloned from brain (Yamashita et al., 1997) .
Recently, PTR4 was cloned from human brain (GenBank accesion no. AY038999).
However, it has not been clarified yet whether PEPT2, PHT1 or PTR4 exists at the BBB.
In our study, remains bleak: survival for less than 1 year (Saleh et al., 2000) . Therefore, new therapeutic strategies need to be developed for gliomas. It was reported that metalloprotease inhibitors, including puromycin and bestatin, induce apoptosis in glioma cells (Schlapbach and Fontana, 1997) . Bestatin is an anticancer agent which is transported by PEPT1. Although, hPEPT1 is not expressed in the brain tissues (Liang et al., 1995) , heterologous expression of PEPT1 at the BBB may allow bestatin to enter the brain efficiently across the BBB. Furthermore, this system could also be applicable to a new melphalan prodrug designed for tumor-selective activation (Kerr et al., 1998) .
However, it is not clear whether heterologous expression of PEPT1 by adenovirus is safe for treatment of disease. The drug delivery system reported here might be This article has not been copyedited and formatted. The final version may differ from this version. We think that the feasibility of this approach for human therapeutic intervention is dependent not only on the safety of transient expression of hPEPT1 by adenovirus, but also on whether any alternative is available to the patient. Many pharmacologically effective peptide-mimetic drugs have been developed, but the BBB permeability of peptides is extremely low, even though expression of some peptide transporter genes at the BBB has been reported. Importantly, the substrate recognition spectrum of oligopeptide transporter hPEPT1 is extremely broad. As reported recently, PEPT1
accepts not only traditional peptide-mimetic agents, but also valacyclovir, 4-aminophenyl, delta-aminolevulinic acid, 6-aminohexanoic acid and so on. These observations suggest that a peptide-bond is not essential for substrates of this transporter (Balimane et al., 1998) . Accordingly, novel non-peptide PEPT1 substrates with pharmacological activity in the brain could also be candidates for this approach.
BBB-specific exogenous gene expression will provide unique opportunities to deliver drugs from the systemic circulation to the brain by specific expression of a peptide transporter at the BBB, and also to study the physiological function of the BBB. The expression of BBB markers, for example GLUT1, has been investigated (Board, 1996) .
The criterion for a BBB-specific gene is expression principally, though not necessarily exclusively, at the BBB (Pardridge et al., 1990) . Papoutsi et al. reported that tumor cells induced the expression of neurothelin/HT7 (but not of glucose transporter-1), a marker of blood-brain-barrier-forming endothelial cells (Papuotsi et al., 2000) . Regulation of such BBB-specific genes by promoters or enhancers is poorly understood. Promoters are an important determinant of the amount and rate of expression after gene transfer. In our present study, we used adenovirus vectors driven by CMV (cytomegalovirus)
promoter. The CMV major immediate early promoter / enhancer drives constitutive The onset and duration of transgene expression are important to evaluate the usefulness of a selected transporter in normal rats. In our previous experiment, the duration of expression of AdGFP was 4 weeks in mouse liver (data not shown). In the present study, we focused on evaluating the expression and function of hPEPT1 in the rat brain 3 days after adenoviral transduction. Further investigation of the onset and duration of transgene expression is required to optimize the concentration of hPEPT1 substrates in the brain Also, better methods are required to control the transgene expression.
In conclusion, we have demonstrated the feasibility of a novel strategy for enhanced drug delivery to the brain by utilizing adenovirus-mediated heterologous expression of an oligopeptide transporter gene. This system is expected to be applicable for the studies of the function of human transporter genes in animal models. This system may also be applicable to chemically modified substrates that are recognized by PEPT1, because PEPT1 accepts a wide range of peptide and peptide-like substances as substrates.
This article has not been copyedited and formatted. The final version may differ from this version. Expression of hPEPT1-EYFP fusion protein in RBEC1 after adenovirus-transduction in the presence of various additives. Non-transduced RBEC1 was used as a control.
(A) control, (B) 3000 molecules of poly-L-lysine to one adenovirus particle, (C) 5% alpha-cyclodextrin, (D) 1.8% beta-cyclodextrin, (E) 5% dimethyl beta-cyclodextrin, (F) 5% 2-hydroxypropyl beta-cyclodextrin, (G) 10% gamma-cyclodextrin, (H) 15%
Poloxamer 407. RBEC1 at 80-90% confluence were transduced with AdhPEPT1-EYFP at MOI 100 in the presence of various additives. After 24 hours' transduction, RBEC1
were observed by fluorescence microscopy. Bar = 20 µm. 
